{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:59:03Z","timestamp":1790693943435,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coi.2026.102852","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:22:19Z","timestamp":1790688139000},"page":"102852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Autoimmune diseases: distinct disorders or diverse manifestations of a common pathogenic process?"],"prefix":"10.1016","volume":"103","author":[{"given":"Haralampos M","family":"Moutsopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102852_bib1","first-page":"154","article-title":"Natural autoantibodies: from \u201chorror autotoxicus\u201d to \u201cgnothi seauton","volume":"12","author":"Avrameas","year":"1991","journal-title":"Immunol Today"},{"key":"10.1016\/j.coi.2026.102852_sbref2","first-page":"89","article-title":"Natural autoantibodies in regulation of immune homeostasis and autoimmune diseases","volume":"1","author":"Baccal\u00e0","year":"2024"},{"key":"10.1016\/j.coi.2026.102852_sbref3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1626082","article-title":"Autoimmune disease: genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies?","volume":"16","author":"Kumar","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib4","first-page":"798029","article-title":"Environmental triggers and autoimmunity","volume":"2014","author":"Vojdani","year":"2014","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.coi.2026.102852_sbref5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/v15030782","article-title":"The role of viral infections in the onset of autoimmune diseases","volume":"15","author":"Shirafkan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.coi.2026.102852_sbref6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001803","article-title":"Identifying immunostimulatory herbal supplements that may flare autoimmune skin diseases: a systematic scoping review","volume":"12","author":"Weiner","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102852_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/ard.2007.084152","article-title":"Stress, coping strategies and social support in patients with primary Sjogren\u2019s syndrome prior to disease onset: a retrospective case-control study","volume":"68","author":"Karaiskos","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1873-3468.12933","article-title":"How stress contributes to autoimmunity-lessons from Sj\u00f6gren\u2019s syndrome","volume":"592","author":"Skopouli","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coi.2026.102852_sbref9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.33549\/physiolres.935804","article-title":"Stress and the immune system: insights from psychoneuroimmunology","volume":"75","author":"Ozaniak Strizova","year":"2026","journal-title":"Physiol Res"},{"key":"10.1016\/j.coi.2026.102852_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01320","article-title":"Natural autoantibodies: an undersugn hero of the immune system and autoimmune disorders \u2014 A point of view","volume":"9","author":"Avrameas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI14452","article-title":"Autoantibodies as predictors of disease","volume":"108","author":"Leslie","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2026.102852_bib13","first-page":"175","article-title":"Development of auto-antibodies before the clinical onset of systemic lupus erythematosus","volume":"25","author":"Arbuckle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102852_bib14","series-title":"Immunology and Rheumatology in Questions","author":"Moutsopoulos","year":"2021"},{"key":"10.1016\/j.coi.2026.102852_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_sbref16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5114\/reum.2022.114186","article-title":"Methods of assessment of joint involvement in various systemic connective tissue diseases","volume":"60","author":"Kardas","year":"2022","journal-title":"Reumatologia"},{"key":"10.1016\/j.coi.2026.102852_sbref17","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2026.102803","article-title":"Raynaud\u2019s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy","volume":"101","author":"Moutsopoulos","year":"2026","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/20734735.0203-2020","article-title":"Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases","volume":"16","author":"Yao","year":"2020","journal-title":"Breathe"},{"key":"10.1016\/j.coi.2026.102852_sbref19","doi-asserted-by":"crossref","first-page":"240171","DOI":"10.1183\/20734735.0171-2024","article-title":"Systemic autoimmune rheumatic diseases-associated interstitial lung disease: a pulmonologist\u2019s perspective","volume":"21","author":"Boyle","year":"2025","journal-title":"Breathe"},{"key":"10.1016\/j.coi.2026.102852_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.12.011","article-title":"A comprehensive evaluation for the treatment of lupus nephritis","volume":"78","author":"Zampeli","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102852_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0002-9343(78)90449-7","article-title":"Immune complex glomerulonephritis in sicca syndrome","volume":"64","author":"Moutsopoulos","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.coi.2026.102852_sbref22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ncl.2021.08.007","article-title":"Autoimmune meningitis and encephalitis","volume":"40","author":"Richie","year":"2022","journal-title":"Neurol Clin"},{"key":"10.1016\/j.coi.2026.102852_sbref23","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107019","article-title":"Clinical, imaging, and immunological features of GFAP astrocytopathy: a systematic review with regional comparison","volume":"107","author":"Uawithya","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.coi.2026.102852_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.31138\/mjr.270324.tis","article-title":"Type I interferons in systemic autoimmune rheumatic diseases: pathogenesis, clinical features and treatment options","volume":"30","author":"Drougkas","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.coi.2026.102852_sbref25","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1152\/physrev.00047.2024","article-title":"Type I interferons in health and disease: molecular aspects and clinical implications","volume":"105","author":"Mavragani","year":"2025","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coi.2026.102852_bib26","doi-asserted-by":"crossref","unstructured":"A. Tesser, P. Bocca, M. Ulivi, A. Pin, C. Pastorino, D. Cangelosi, E. Santori, E. Drago, R. Caorsi, F. Candotti, et al., Type I interferon signature: a quantitative standardized method for clinical application, Clin Exp Immunol, 219, 2025:uxaf018.","DOI":"10.1093\/cei\/uxaf018"},{"key":"10.1016\/j.coi.2026.102852_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10238-020-00606-7","article-title":"Mixed connective tissue disease \u201d: a condition in search of an identity","volume":"20","author":"Alves","year":"2020","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.coi.2026.102852_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1494-7","article-title":"Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study","volume":"19","author":"Reiseter","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102852_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7326\/0003-4819-92-2-212","article-title":"Sjogren\u2019s syndrome (Sicca syndrome): current issues","volume":"92","author":"Moutsopoulos","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2026.102852_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.coi.2026.102852_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1756-185X.13454","article-title":"Polyautoimmunity in rheumatological conditions","volume":"22","author":"Matusiewicz","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","article-title":"Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study","volume":"75","author":"Avouac","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib33","first-page":"149","article-title":"Evolution of one systemic rheumatic disease into another: scleroderma evolving to eosinophilic fasciitis with myositis","volume":"119","author":"Zampeli","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102852_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17474086.2020.1754791","article-title":"Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures","volume":"13","author":"Barcellini","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.coi.2026.102852_sbref34","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1017\/erm.2025.11","article-title":"Unveiling the therapeutic potential: targeting fibroblast-like synoviocytes in rheumatoid arthritis","volume":"27","author":"Yue","year":"2025","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.coi.2026.102852_sbref35","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2026.102815","article-title":"The epithelial cell in Sj\u00f6gren\u2019s syndrome: from passive target to orchestrator of autoimmune reactivity","volume":"102","author":"Moutsopoulos","year":"2026","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib37","series-title":"Harrison\u2019s Principles of Internal Medicine","article-title":"Multiple sclerosis and other demyelinating diseases","author":"Hauser","year":"2022"},{"key":"10.1016\/j.coi.2026.102852_bib38","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102852_bib39","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0035-1548832","article-title":"The pathogenesis of Hashimoto\u2019s thyroiditis: further developments in our understanding","volume":"47","author":"Ajjan","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.coi.2026.102852_bib40","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102852_sbref40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41577-024-01043-3","article-title":"Single-cell analysis in rheumatic and allergic diseases: insights for clinical practice","volume":"24","author":"Nishide","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cca.2014.06.015","article-title":"Autoantibodies in pre-clinical autoimmune disease","volume":"437","author":"Hu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.coi.2026.102852_sbref42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1003054","article-title":"Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sj\u00f6gren\u2019s syndrome: a critical review","volume":"13","author":"V\u00edlchez-Oya","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib44","series-title":"Autoantibodies","first-page":"2013","author":"Shoenfeld","year":"2013"},{"key":"10.1016\/j.coi.2026.102852_bib45","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2026.102852_sbref45","first-page":"S134","article-title":"Anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations","volume":"38","author":"Zampeli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102852_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.pathol.2019.03.007","article-title":"Autoantibodies in interstitial lung diseases","volume":"51","author":"Stevenson","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.coi.2026.102852_bib48","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League Against Rheumatism \/ American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","article-title":"Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)","volume":"52","author":"Sharp","year":"1972","journal-title":"Am J Med"},{"key":"10.1016\/j.coi.2026.102852_sbref49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100141","article-title":"Autoantibodies in the disease criteria for systemic sclerosis: the need for specification for optimal application","volume":"5","author":"Damoiseaux","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.coi.2026.102852_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: Implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/annotation\/2e462817-ab93-4d78-95a4-1d8b9d172971","article-title":"Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis","volume":"7","author":"Sokolove","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102852_bib53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/08830185.2014.917411","article-title":"Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection","volume":"33","author":"Cunningham","year":"2014","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clim.2019.07.007","article-title":"West Nile Virus infection triggering autoimmune encephalitis: pathophysiological and therapeutic implications","volume":"207","author":"Karagianni","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/358155a0","article-title":"Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen","volume":"358","author":"Lehmann","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.coi.2026.102852_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/sji.12657","article-title":"Evolution from one autoimmune disorder to another. Epitope spreading?","volume":"87","author":"Karagianni","year":"2018","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.012","article-title":"Bystander activation and autoimmunity","volume":"103","author":"Pacheco","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102852_sbref57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases","volume":"23","author":"Miyauchi","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2026.102852_sbref58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s40588-023-00213-6","article-title":"Gut microbiota and autoimmune diseases: mechanisms, treatment, challenges, and future recommendations","volume":"11","author":"Sadeghpour Heravi","year":"2024","journal-title":"Curr Clin Microbiol Rep"},{"key":"10.1016\/j.coi.2026.102852_bib60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/138920207783591690","article-title":"The HLA region and autoimmune disease: associations and mechanisms of action","volume":"8","author":"Gough","year":"2007","journal-title":"Curr Genom"},{"key":"10.1016\/j.coi.2026.102852_bib61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.42.5.533","article-title":"HLA DR alloantigens in different subsets of patients with Sjogren\u2019s syndrome and in family members","volume":"42","author":"Mann","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib62","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.immunol.021908.132653","article-title":"Recent advances in the genetics of autoimmune disease","volume":"27","author":"Gregersen","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib63","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2015.05.008","article-title":"Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy","volume":"14","author":"Zhang","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102852_sbref63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.05.008","article-title":"Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases","author":"Fan","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.822996","article-title":"Antigen reactivity and clinical significance of autoantibodies directed against the pyruvate dehydrogenase antigen complex in patients with connective tissue disease","volume":"13","author":"Ceribelli","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_sbref65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2026.102852_sbref66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102852_bib68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2026.102852_bib69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.142.1.70","article-title":"Improvement in dermatomyositis rash associated with the use of antiestrogen medication","volume":"142","author":"Sereda","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coi.2026.102852_bib70","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coi.2026.102852_bib71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2215\/CJN.03640412","article-title":"Lupus nephritis: maintenance therapy for lupus nephritis-do we now have a plan?","volume":"8","author":"Lenz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102852_bib72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102852_bib73","doi-asserted-by":"crossref","unstructured":"J. Shin, Il, H. Li, S. Park, J.W. Yang, K.H. Lee, Y. Jo, et al., Induction and maintenance treatment of lupus nephritis: a comprehensive review of meta-analyses, J Clin Med, 11, 2022,343.","DOI":"10.3390\/jcm11020343"},{"key":"10.1016\/j.coi.2026.102852_bib74","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.4049\/jimmunol.119.5.1639","article-title":"Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM","volume":"119","author":"Moutsopoulos","year":"1977","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.150.1.31","article-title":"CBA\/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice","volume":"150","author":"Taurog","year":"1979","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2026.102852_sbref74","first-page":"1","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102852_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2026.102852_sbref76","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102852_sbref77","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2026.102852_sbref78","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-022-01880-6","article-title":"The promise of precision medicine in rheumatology","volume":"28","author":"Guthridge","year":"2022","journal-title":"Nat Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:42Z","timestamp":1790692242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":80,"alternative-id":["S0952791526001299"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102852","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune diseases: distinct disorders or diverse manifestations of a common pathogenic process?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102852"}}